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Introduction
Despite an abundance of antihypertensive medica-
tions with proven efﬁcacy, up to two-thirds of trea-
ted hypertensive patients do not achieve blood
pressure (BP) control (1,2). The failure to take medi-
cations according to the prescribed regimen (non-
adherence), and even worse, the discontinuation of
treatment (non-persistence) are the main factors
contributing to this problem (3–9). Observational
data from community practice reveal that non-per-
sistence with antihypertensive medications is a signif-
icant problem (10). Up to 25% of patients with
hypertension discontinue their medications within
months of their ﬁrst prescription (11,12) – a modiﬁ-
able behaviour (6,10) that has serious clinical (13,14)
and economic (15) consequences. Failure to control
hypertension in the USA has been estimated to cost
US $467 million among treated patients and US
$964 million if both treated and untreated are con-
sidered (16). In Canada (17) and the USA (18), the
estimated average annual medical cost per patient for
the treatment of hypertension is approximately
$4000 USD. Given the cost and the medical implica-
tions associated with uncontrolled BP, the US gov-
ernment has embarked on a national initiative (2010
initiative) to control 50% of treated hypertensive
patients by the year 2010 (19).
That so many patients risk serious and costly car-
diovascular complications by discontinuing or misus-
ing their medications (20), suggests that increased
patient support and education could improve
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SUMMARY
Aims: The Blood Pressure Success Zone (BPSZ) Program, a nationwide initiative,
provides education in addition to a complimentary trial of one of three antihyper-
tensive medications. The BPSZ Longitudinal Observational Study of Success (BPSZ-
BLISS) aims to evaluate blood pressure (BP) control, adherence, persistence and
patient satisfaction in a representative subset of BPSZ Program participants. The
BPSZ-BLISS study design is described here. Methods: A total of 20,000 physicians
were invited to participate in the study. Using a call centre supported Interactive
Voice Response System (IVRS), physicians report BP and other data at enrolment
and every usual care visit up to 12 ± 2 months; subjects self-report BPs, persis-
tence, adherence and treatment satisfaction at 3, 6 and 12 months post-BPSZ Pro-
gram enrolment. In addition to BPSZ Program enrolment medications, physicians
prescribe antihypertensive medications and schedule visits as per usual care. The
General Electric Healthcare database will be used as an external reference.
Results: After 18 months, over 700 IRB approved physicians consented and
enrolled 10,067 eligible subjects (48% male; mean age 56 years; 27% newly diag-
nosed); 97% of physicians and 78% of subjects successfully entered IVRS enrol-
ment data. Automated IVRS validations have maintained data quality (< 5% error
on key variables). Enrolment was closed 30 April 2007; study completion is sched-
uled for June 2008. Conclusions: The evaluation of large-scale health education
programmes requires innovative methodologies and data management and quality
control processes. The BPSZ-BLISS design can provide insights into the conceptuali-
sation and planning of similar studies.
What’s known
Educating patients with hypertension can help
improve blood pressure control rates.
What’s new
This paper contributes a detailed description of a
methodology to assess, naturalistically, real-world
health outcomes in a usual care population of
more than 10,000 patients participating in a large-
scale health education initiative related to the
management of hypertension.
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educating patients about their health, the conse-
quences of hypertension, and ways to optimise treat-
ment can improve BP control rates (21–25). A recent
review of 56 randomised clinical trials that deter-
mined the effectiveness of interventions to improve
BP control noted that the methodological quality of
these studies were poor to moderate, and indeed
only one trial, the Hypertension Detection and Fol-
low-up study was conducted on a large-scale real-
world population (26).
The Blood Pressure Success Zone (BPSZ) Program
is a comprehensive, patient-centred, treatment, edu-
cation and support programme designed to improve
persistence and adherence with antihypertensive
medication. The BPSZ Program, offered to more
than 40,000 US physicians since July 2005, will enrol
more than 100,000 patients with newly diagnosed or
uncontrolled chronic hypertension. The BP Success
Zone Program was designed by behavioural psychol-
ogists based on a proven model of self-efﬁcacy, or
the belief that one’s own health behaviours are under
one’s own control.
Patients can join the BP Success Zone Program once
they have received an enrolment kit from their doctor,
which includes a complimentary product of either
benazepril⁄amlodipine ﬁxed combination (Lotrel
 ;
Novartis Pharmaceuticals Corporation, East Hanover,
NJ, USA), valsartan (Diovan
 ; Novartis Pharmaceuti-
cals Corporation) or valsartan⁄HCTZ (co-Diovan
 ),
selected at the discretion of the physician for the trial
of up to 30 days. The enrolled patients can avail up to
$10 off of a ﬁrst prescription for any of these products
or a 14-day voucher, a $40 rebate for an Omron
  BP
monitor (Omron Corporation, Kyoto, Japan), a guar-
antee of reaching BP goal or getting the ﬁrst 4 months
of out-of-pocket prescription costs refunded, patient
education delivered via mailings customised to partici-
pant demographics and attitudes and behaviours, as
well as web tools to help manage their hypertension.
When patients enrol in the BPSZ Program, they can
choose among one of ﬁve Healthy Life-Style Action
Plans, each of which consists of ﬁve communications
to the patient via print or e-mail. The communications
are in the form of newsletters that educate patients on
that particular plan.
Although prior evidence (21–25) suggests that an
initiative such as the BPSZ Program will contribute
positively to patient health, to date, clinical outcome
data have not been collected. These data are essential,
however, for quantifying the impact of this pro-
gramme. The main objective of the BPSZ Longitudi-
nal Observational Study of Success (BPSZ-BLISS),
therefore, was to evaluate BP control, adherence, per-
sistence, and patient satisfaction as naturalistically as
possible in a representative subset of the BPSZ Pro-
gram participants. The objective of this manuscript
is to describe the design and methods of the BPSZ-
BLISS study.
Methods
Background
The BPSZ Program, which is still ongoing, has been
offered to more than 100,000 patients with hyperten-
sion in the usual care setting to help achieve and
maintain a BP goal as recommended by the JNC-VII
guidelines (27). Physicians invite patients from their
medical practices to participate in the BPSZ Program
and provide interested patients with a Program Kit
(Novartis Pharmaceuticals Corporation) to enrol.
The Program Kit includes some customised educa-
tional materials, a guarantee of reaching the BP goal
or getting the ﬁrst 4 months of out-of-pocket pre-
scription costs refunded, a $10 coupon for the ﬁrst
prescription, a $40 rebate for an Omron
  BP Moni-
tor and up to 30 days of medication [either benazep-
ril⁄amlodipine ﬁxed combination (Lotrel
 ), valsartan
(Diovan
 ) or valsartan⁄HCTZ (co-Diovan
 ) selected
at the discretion of the physician].
To enrol in the BPSZ Program, patients must be
willing to receive a trial prescription for either bena-
zepril⁄amlodipine ﬁxed combination, valsartan, or
valsartan HCTZ alone or in combination with other
antihypertensive medications. Patients must also be
new to the programme and have either a new diagno-
sis of hypertension (antihypertensive naı ¨ve patient), or
an established diagnosis of hypertension that is uncon-
trolled on antihypertensive medication. The diagnosis
of lack of control is deﬁned as systolic BP ‡
140 mmHg and⁄or diastolic BP ‡ 90 mmHg except in
the presence of diabetes or renal disease where the lim-
its are 130 mmHg for systolic and 80 mmHg for dia-
stolic BP. By design, in the BPSZ-BLISS study,
comparisons will not be made with regards to differ-
ences in efﬁcacy or effectiveness of speciﬁc antihyper-
tension medications. More importantly, to avoid the
perception of bias by the sponsor, multiple checks and
balances have been implemented including oversight
by an academic Steering Committee.
Within 18 months of launch of the study, over
700 IRB approved physicians consented and enrolled
10,067 eligible subjects (48% male; mean age
56 years; 27% newly diagnosed); 97% of physicians
and 78% of subjects successfully entered Interactive
Voice Response System (IVRS) enrolment data.
Automated IVRS validations maintained data quality
(< 5% error on key variables). Enrolment was closed
on 30 April 2007; the study was completed in June
2008. Details of the design and methods of the
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baseline characteristics of the study cohort will be
reported in a separate publication.
BPSZ-BLISS design overview
Blood Pressure Success Zone-BLISS was designed to
evaluate the effect of the BPSZ Program on key out-
come measures such as the proportion of patients
achieving BP control, medication persistence, treat-
ment adherence and satisfaction. This observational,
multicentre study was approved by a central ethics
review board. The only study-speciﬁc enrolment cri-
teria, which differed from those of the BPSZ Pro-
gram, were the need to be ﬂuent in either English or
Spanish and, that study subjects had a functioning
touch-tone telephone.
To enrol in the BPSZ-BLISS study, subjects must
have provided informed consent and then enrolled
themselves in the BPSZ Program as per Program
guidelines. Study physicians must also have activated
the study identiﬁcation number of each consenting
subject in the BPSZ-BLISS database. Subjects may
have voluntarily withdrawn from the study at any
time but withdrawal did not preclude ongoing par-
ticipation in the BPSZ Program. A minimum of
10,067 subjects, approximately a 10% sample of
BPSZ Program participants, were enrolled to allow
for the estimation of BP control rates at various time
points in sub-populations deﬁned by age, gender,
ethnicity, hypertension status (new vs. chronic) and
presence of diabetes or renal disease.
Investigational drugs were not administered to
study subjects, although at baseline, BPSZ Program
medications must have been prescribed alone, or in
combination with other concomitant antihyperten-
sives, as per BPSZ Program enrolment criteria. Consis-
tent with the observational design, however, treatment
for hypertension was managed by the physician as per
routine care following the baseline (enrolment) visit.
More speciﬁcally, choice of antihypertensive drug,
dose, and treatment regimen in individual patients
was determined by the managing physician through-
out the study period. Following the baseline visit,
BPSZ Program medications could have been removed
from the treatment regimen at the discretion of the
physician. Physicians were instructed to report serious
adverse events as per standard medical practice.
To provide a reference for the BP control rates
documented in BPSZ-BLISS, an external reference
group (28,29) will be created by identifying a cohort
of similar patients whose management is recorded in
the General Electric (GE) Healthcare Electronic Med-
ical Record (EMR) database. This is a comprehensive
national dataset containing both clinical (e.g. BP)
and administrative (e.g. MD visits) information (30).
Recruitment and training
Approximately 20,000 physicians enrolled in the
BPSZ Program were randomly selected from a list of
40,000 physicians who had previously participated in
Novartis-sponsored hypertension health education
initiatives and invited to participate in BPSZ-BLISS.
The ﬁrst 2000 physicians who expressed interest in
participating completed the appropriate documents
and underwent the study training to enrol patients.
Contracting, IRB applications and IRB renewals were
supported by an internet-based document manage-
ment system (Synovate ViewsCast, Chicago, IL).
Upon receipt of the IRB applications via the internet,
physician information was provided to a central IRB
agency (IRB Services, Aurora, Canada) responsible
for study approvals.
Once IRB approved and trained, physicians were
provided with BPSZ-BLISS materials. Physicians
invited into the study only those patients who had
already decided to participate in the BPSZ Program.
Participating physicians were remunerated quarterly
for a total of USD $200 per enrolled patient. So as
not to encourage additional medical visits outside of
usual care, payments were made quarterly in full
irrespective of whether follow-up data were entered,
or subjects had completed the study.
Study conduct
Data collection and management
Blood Pressure Success Zone-BLISS data were col-
lected and managed electronically using an IVRS –
an integration of computer-automated interviewing
with touch-tone telephone service (Synovate Views-
Cast). The IVRS, available 24 h a day, 7 days a week,
allows for entry of information directly into the elec-
tronic database. Call centre representatives were also
available via the IVRS routing menu to assist callers
in between data entry periods. Access to the IVRS
was via a toll-free telephone number. To ensure
security, a link was created by the physician during
the baseline study visit using the participant’s BPSZ
Program identiﬁcation number and date of birth.
To facilitate delivery of data entry reminders by
the IVRS and call centre provider, patients must have
consented to the inclusion of their name, home
address and phone number. Only representatives of
the IVRS call centre – not the study sponsor or its
representatives – had access to this information.
Patients who did not enrol in the BPSZ Program
within 7 days of the BPSZ-BLISS enrolment visit
were issued an automated telephone message. A sim-
ilar reminder was issued to all subjects 3 days prior
to each 3, 6 and 12 months visit. If data were not
entered within 6 days of this prompt, then call centre
Re-use of this article is
permitted in accordance with
the Creative Commons Deed,
Attribution 2.5, which does not
permit commercial exploitation.
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reach the subject by phone over a 1-week period.
With respect to the physician-reported data, the
number and timing of healthcare consultations with
subjects over the study period were not mandated by
the protocol but physicians were sent generic
reminders that study data should be entered into the
IVRS following all routine care visits.
Physicians received prepackaged patient study
boxes (one per subject) containing both the physi-
cian’s worksheets, to be used during all visits to
record study data, and all the materials a subject
needed to participate. For example, each study sub-
ject received a box that included an instruction
booklet (in English or Spanish), a complimentary BP
monitor, a wallet card to record BP values, and a
standard BPSZ Program kit, containing a 30 day
sample of valsartan, valsartan HCTZ or benazep-
ril⁄amlodipine ﬁxed combination (selected and pre-
scribed at the discretion of the physician), as well as
a $10 coupon off for the ﬁrst prescription. The kit
containing medication was not tailored in any way
for study participants. It was exactly the same kit
that all BPSZ Program participants received even if
they were not enrolled in the BPSZ-BLISS study.
BPSZ-BLISS study baseline (enrolment) visit
At the BPSZ-BLISS baseline enrolment visit, the phy-
sician removed a two-ply informed consent form
and a set of worksheets (which parallelled the IVRS
data entry script) from the study box and clipped
them to the inside of the patient’s medical chart.
These worksheets were used during the baseline visit
and at every usual care visit thereafter to record
study data prior to contacting the IVRS.
After obtaining an informed consent from the
patient, the physician initiated the BPSZ-BLISS
study enrolment process by activating the patient’s
BPSZ Program membership identiﬁcation number
found on the BPSZ Program kit and, for security
purposes, linked this number to the subject’s date
of birth. The following data were entered into the
IVRS: most recent hypertension medication, dose
and daily regimen (from last ofﬁce visit, if applica-
ble), current BP (from baseline study visit) and
study enrolment antihypertensive medication(s)
(valsartan, valsartan HCTZ or benazepril⁄amlodi-
pine ﬁxed combination, and other concomitant
antihypertensives), dose(s) and daily regimen. Sys-
tolic and diastolic BPs were measured by study
physicians using routine practice – no standardised
method was mandated by the study protocol,
although the type of BP monitor typically used at
each physician’s ofﬁce was documented. During
this visit, the subjects also measured their own BP
using the complimentary home BP monitor and
recorded these values in the wallet card provided.
BPSZ program patient self-enrolment
To be eligible for the BPSZ-BLISS study enrolment
process, patients must have self-enrolled into the
BPSZ Program. To this end, subjects contacted the
study IVRS, entered their subject identiﬁcation num-
ber and date of birth, and then enter their patient-
reported data before being transferred to the BPSZ
Program enrolment call centre. Prior to this transfer,
the patient was asked if he⁄she had started taking
his⁄her new antihypertensive medications prescribed
during the baseline visit, and if so, the date that the
medication was started. Each subject also entered
his⁄her systolic and diastolic BP measured by the sub-
ject during the enrolment visit. To ensure a relevant
subject-reported enrolment BP, if the subject called to
enrol in the programme more than 7 days poststudy
enrolment, the subject was also asked to enter a BP
reading obtained within the previous 7-day period.
Upon completion of this IVRS segment, the subject
was transferred to a live BPSZ Program agent
(Figure 1). Once enrolled in the Program, in addition
to BPSZ Program materials, subjects eligible for the
study were also mailed a personalised BPSZ-BLISS
study welcome letter and a magnet which speciﬁed the
patient’s actual 3-, 6- and 12-month calendar dates that
study data should have been entered into the IVRS.
Follow-up visits
During every subsequent usual care visit over the
course of the 12 (±2)-month study period, physi-
cians also reported the patient’s BP and any changes
to the baseline antihypertensive medication(s)
including dose, daily regimen and reason(s) for
change such as contraindications, or the discretion of
the physician. Patient height, weight and waist cir-
cumference were also measured and reported. All
data were entered ﬁrst on the appropriate worksheet
and then entered into the IVRS. At 3, 6 and
12 months ()3, +10 days) postenrolment in the
BPSZ Program, patients entered data related to BP,
persistence with, and adherence to antihypertensive
medication as well as satisfaction with treatment. If
the patient indicated during the 3-, 6- and 12-month
IVRS assessment that he⁄she had not stopped taking
his⁄her antihypertensive medication, the patient
completed the Modiﬁed Morisky Scale (seven items)
(31,32), a measure of treatment adherence, using
his⁄her own pattern of antihypertensive medication
use as a reference. Patients still persistent at these
time points also completed a modiﬁed version of the
Treatment Satisfaction Questionnaire for Medication
(TSQM) (33). In the modiﬁed questionnaire, only
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(items 9–11) and global satisfaction (items 12–14)
sub-scales were administered. The TSQM is a psy-
chometrically robust instrument, which taps into the
most important dimensions of patients’ experiences
with their medication. A manuscript reporting the
psychometric properties of the modiﬁed scale is cur-
rently in preparation. The BPSZ-BLISS study assess-
ment schedule is presented in Figure 2.
Statistical analyses
Analyses will be performed on data obtained from
patients who were successfully enrolled in the BPSZ-
BLISS study and the BPSZ Program, and for whom
data on BP measurements, as well as persistence,
adherence and satisfaction to antihypertensive medi-
cation during follow-up was reported.
The study population will be characterised with
respect to cohort disposition, the distribution of the
age, gender, ethnicity, weight, height, waist circum-
ference, prior comorbidities, baseline BP, hyperten-
sion status, diabetes status and treatment prescribed
by the physician at the baseline study visit. These will
be presented and summarised with appropriate
descriptive statistics (mean, standard deviation, med-
ian and range for continuous variables; number and
percentage for categorical variables).
Analyses will examine outcomes in the overall
population as well as within subgroups deﬁned by
gender, age (e.g. 18–44 years of age; 45–54 years of
age; 55–64 years of age and ‡ 65 years of age), eth-
nicity (e.g. Caucasian; African American; Hispanic
and other), hypertension status (newly diagnosed vs.
chronic patients) and other prior comorbidities.
Primary analyses of BP control will be based on
physician-reported data. Deﬁnition of BP control will
be based on the JNC-VII guidelines (Table 1) (27).
Imputation, or other appropriate methods, will be
undertaken if a high rate of missing BP measure-
ments is found. Last-observation-carried-forward,
linear interpolation and multiple imputation will be
considered, depending on the patterns of missing
data. The proportion of patients who achieved BP
control over time will be described and summarised
using Kaplan–Meier curves for the overall population
and subgroups. Differences between subgroups will
be tested using the log-rank and Wilcoxon tests. A
proportional hazards model will be ﬁtted to identify
predictors of time to control. Alternative measures of
BP control, such as time to control, or change from
baseline will also be examined.
Data on persistence, adherence and satisfaction
were reported by patients at 3, 6, and 12 months. At
each time point, the number and proportion of
Figure 1 Overview of BPSZ-BLISS Study and BPSZ Program self-enrolment. BPSZ-BLISS, Blood Pressure Success Zone
Longitudinal Observational Study of Success
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in the study and by subgroups. Adherence and satis-
faction with treatment will be described for patients
who are persistent at months 3, 6 and 12 months.
Adherence is measured with the Morisky Scale
(31,32), with scores ranging from zero to seven. A
modiﬁed version of the TQSM (33) is used to evalu-
ate satisfaction with total effectiveness, convenience
and global satisfaction, with scores ranging from 0 to
100 for each sub-scale. The distribution of scores will
be described in terms of the mean, standard devia-
tion and quartiles in the overall population and by
subgroups. The proportion reporting high, moderate
or low adherence (deﬁned as Morisky scale score of
7, 5 to <7, <5 or below, respectively) and satisfaction
will also be described. Given the volume and scope
of data related to patient demographics and the
management of hypertension, which will be collected
in BPSZ-BLISS, numerous analyses related to usual
care management patterns by physician and⁄or
patient characteristics are also anticipated.
Conclusions
The BPSZ-BLISS study was designed to evaluate the
impact of the BPSZ Program, a prospective interven-
tion for the management of hypertension using an
external reference control group. This design aims to
achieve a balance between the need for some control
to properly collect data from a large real world pop-
ulation of patients and the need to collect these data,
naturalistically, by minimising interference with phy-
sician and subject behaviour. As such, observational
and naturalistic principles are central to the BPSZ-
BLISS study design. Apart from prescribing the BPSZ
Program antihypertensive medication alone or in
combination with other concomitant antihyperten-
sive medication at the baseline visit, physicians were
free to administer additional or replacement antihy-
pertensive medications, adjust dosing regimens and
schedule ofﬁce visits at their professional discretion.
Study physicians were instructed to evaluate BP and
other clinical variables as per routine care – no stan-
dardised methods were imposed. On the patient side,
to minimise response bias, patients responded to
questions related to BP, persistence, adherence and
treatment satisfaction via the IVRS, far and away
from the potential inﬂuence of their healthcare pro-
fessionals who treat them.
One of the important features of the BPSZ-BLISS
study design is that it permitted the collection of BP
values from both physicians and patients over a 10-
to 14-month period. Data such as these will allow
for analyses of BP control rates in actual practice
resulting in estimates of proportions of patients con-
trolled and time to control (6). The comparison of
Figure 2 BPSZ-BLISS design overview. IVRS, Interactive Voice Response System; BPSZ-BLISS, Blood Pressure Success
Zone Longitudinal Observational Study of Success
Table 1 Summary of blood pressure control deﬁnitions
(27)
BP classiﬁcation SBP (mmHg) DBP (mmHg)
Normal < 120 and < 80
Prehypertensive 120–139 and⁄or 80–89
Stage 1 hypertension 140–159 and⁄or 90–99
Stage 2 hypertension ‡ 160 and⁄or ‡ 100
BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic
blood pressure.
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were assessed and collected in this study, will con-
tribute to a better understanding of ambulatory BP
management. A concern that might be raised is that
patients enrolled in the BPSZ Program are prescribed
an initial regimen that includes an antihypertensive
drug made by the sponsor. To guard against a poten-
tial bias in the interpretation of study results, various
checks and balances were employed. For example,
the analyses of study data will not involve any drug
comparisons with regard to efﬁcacy or effectiveness.
The rates of use of different drugs and combinations
will be reported as a component of the ecology of
the intervention, but comparisons with regard to BP
lowering or clinical events will not be made. These
medications are just one feature of the comprehen-
sive BPSZ Program, and it will not be possible to
evaluate with any validity the relative impact of the
various programme components (e.g. enrolment visit
medication vs. educational materials etc.) on the out-
comes of interest. Furthermore, an academic steering
committee was assembled to provide oversight for
the study, the analytical methods employed, the
interpretation of results, as well as all publications.
Funding sources and potential conﬂicts of interest
have been made transparent. Clearly, these efforts do
not completely diminish the risk of bias, but in our
view, the evaluation of effectiveness that the BPSZ-
BLISS study provides is no different in this regard
than an RCT in which the sponsor’s drug is a com-
parator.
To put the outcomes of the BPSZ-BLISS results in
context, the GE EMR database (30) has been selected
as a suitable source of external reference data. Limi-
tations to externally controlled studies exist, however.
For example, it is difﬁcult to ensure that both the
treatment and control groups are comparable in
terms of demographic and clinical features, diagnos-
tic criteria, disease severity and concomitant treat-
ments – hence bias may be a problem. Moreover,
time as a determinant of outcomes must also be con-
sidered given the potential for changes in treatment
patterns, guidelines and available treatments. Statisti-
cal issues may be complex as techniques such as
regression analyses, propensity scores or selective
sampling must be employed to deal with missing
data and to control confounding variables as much
as possible. The persuasiveness of ﬁndings depends
on a much larger difference in treatment effect and
higher levels of statistical signiﬁcance than would be
considered necessary in a concurrently controlled
trial. Limitations aside, in many circumstances such
as this study, a perfect control group may be impos-
sible to achieve. A separate and subsequent publica-
tion will describe in detail the rationale underlying
this approach and the methods, which will be
employed.
A main premise of this design is that BPSZ-
BLISS study results derived from a 10% sample of
BPSZ-Program participants can be generalised to
the BPSZ Program population as a whole. Accord-
ingly, demographic and clinical characteristics must
be shown to be comparable, and the potential
impact of observer effects on hypertension manage-
ment outcomes in the study cohort must be
explored. With respect to population characteristics,
study selection criteria were designed to match that
of the BPSZ Program and additional restrictive cri-
teria common to randomised and controlled trials
were not employed. Further, study participants
were enrolled from all states that offer the BPSZ
Program and physicians were trained to recruit for
the study only those patients who indicated ﬁrst
that they wanted to enrol in the BPSZ Program.
Regarding observer effects, although BPSZ-BLISS
subjects provided informed consent, a reminder to
them that they were being studied, consent must
also have been provided by all patients enrolling in
the BPSZ Program, even if they were not partici-
pating in the study. In general, while the Haw-
thorne effect (i.e. the impact on behaviour of the
awareness of being observed) may alter study
patient and physician behaviour to some degree,
signiﬁcant observer effects are also present in the
BPSZ Program itself. In fact, the global aim of the
BPSZ Program is to make patients acutely aware
of the medical services and treatments that are
available to them and to remind them on an
ongoing basis of the need for various lifestyle
interventions. Programme participants receive a ser-
ies of tailored mailings, which promote healthy
behaviours and encourage patients to communicate
regularly with their healthcare provider. Thus,
while it is impossible to completely eliminate the
inﬂuence of observation on study outcomes or
even measure this phenomenon, in theory, the dif-
ferential impact of observer effects on study partic-
ipants vs. the same in non-study BPSZ Program
participants may actually be minimal given the
nature of the BPSZ Program intervention.
Data collected as a result of the BPSZ-BLISS study
have resulted in a rich dataset that will support
diverse analyses of usual care hypertension manage-
ment and related clinical and patient-reported out-
comes. Given the very large sample size and inherent
ethnic diversity of the study cohort, BPSZ-BLISS
provides an opportunity for numerous subgroup
analyses of interest, deﬁned both in terms of physi-
cian and subject characteristics. BPSZ-BLISS data will
also support the testing and further development of
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that reﬂect a routine care assessment schedule.
Finally, although the BPSZ-BLISS design has been
tailored to collect data on the outcomes from
patients with hypertension, the main parameters,
infrastructure and methodologies employed could be
adapted to the evaluation of any large-scale health
improvement intervention. At this time, 10,067 eligi-
ble patients have consented and been enrolled in the
study by over 700 participating physicians. Although
study enrolment closed in April 2007, and data col-
lection terminated in June 2008.
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